CO-1686 has demonstrated a good tolerability and promising efficacy against T790M+ epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).
In a large number of samples of lung adenocarcinoma the incidence of RET fusion, as detected by routine diagnostics, was higher than expected, according to a report by Dr Oliver Gautschi of the Clinic for Oncology, Kantonsspital, Luzern, Switzerland.
A group of Italian and Swiss researchers have found a correlation between PD-L1 expression and EGFR mutation, as well as between PD-1 expression and KRAS mutations in a cohort of molecularly selected patients with non-small-cell lung cancer (NSCLC).
A new era of lung cancer therapy is close to dawning, using a new class of drugs that can prevent tumour cells from evading the immune system.
A team of UK and USA researchers, led by Prof. Dean Fennell of the Thoracic Medical Oncology Department, University Hospital of Leicester, UK, performed a prospective exploratory liquid biopsy analysis with the aim of identifying somatic mutations in plasma as predictors of clinical outcome with ganetespib in the GALAXY-1 trial.
Characteristics of Lung Cancers arising in Germline EGFR T790M Mutation Carriers and Relationship to Smoking Status
DENVER –Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC).